Triple Therapy…Can We Replace More With Better?∗  by Valle, Javier A. & Messenger, John C.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 4 . 0 7 9EDITORIAL COMMENTTriple Therapy.
Can We Replace More With Better?*
Javier A. Valle, MD, John C. Messenger, MDSEE PAGE 616T riple therapy, or the use of oral anticoagula-tion (OAC) in addition to dual antiplatelettherapy (DAPT), is common among patients
who have undergone percutaneous coronary inter-
vention (PCI) and have concurrent indications for
anticoagulation, such as atrial ﬁbrillation (AF) or me-
chanical valve replacements. Patients are started on
this therapy because of a concern for thrombotic
events such as myocardial infarction, stent throm-
bosis, or embolic stroke. Unfortunately, this potent
antithrombotic regimen also exposes patients to
increased bleeding. While clinicians were quick to
grasp the dangers of thrombotic events, only recently
have the dangers of bleeding events started to be
truly understood: bleeding is more than just a
nuisance, carrying its own signiﬁcant risk of major
adverse cardiac events (MACE) and mortality (1–3).
Thus, practitioners are left with a clinical con-
undrum, balancing the risks of thrombosis and
bleeding.
Clinicians are encountering this dilemma more
frequently as the indications for both OAC and DAPT
expand. Through efforts to reduce thromboembolic
events, the population of patients with AF and in-
dications for OAC has broadened signiﬁcantly. The
development of the CHA2DS2-VASc (congestive heart
failure, hypertension, age $75 years, diabetes melli-
tus, stroke/transient ischemic attack, vascular dis-
ease, age 65 to 74 years, sex category) risk score also
expanded the number of patients with indications for
anticoagulation (4), as the most recent major societal*Editorials published in the Journal of the American College of Cardiology
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the contents of this paper to disclose.guidelines endorse a lower threshold to start OAC,
using a CHA2DS2-VASc score of 1 as opposed to 2 (5,6).
Concurrently, emerging data support longer duration
of DAPT (7) to reduce stent thrombosis and MACE.
With more patients on OAC and patients on DAPT for
longer periods, the overlap of these 2 populations has
inevitably grown as well. As physicians try to prevent
adverse thrombotic events, more patients are being
treated with more antithrombotic therapy. However,
with the concurrent risk of bleeding, we must ask: is
more antithrombotic therapy better? Or is it time to
replace “more” with “better”?In this issue of the Journal, Hess et al. (8) add to
the growing body of work by examining triple ther-
apy use and its effects on MACE and bleeding. The
available evidence is limited mainly to observational
data but has been inconsistent in its ﬁndings
regarding MACE, with a majority of studies failing to
show an association between use of triple therapy
and lower rates of MACE or mortality. Conversely,
the current data are consistent in showing an asso-
ciation between triple therapy and bleeding events,
with all but 1 study demonstrating increased rates of
bleeding associated with triple therapy use. Hess
et al. found similar relationships, showing a lack of
association between triple therapy use and MACE
risk but a signiﬁcant association with increased
bleeding among older patients with acute myocardial
infarction and AF. Furthermore, although there was
a trend for fewer ischemic strokes in the triple
therapy group, this outcome was counterbalanced by
an increase in hemorrhagic stroke. Although the
question of whether triple therapy is beneﬁcial for
MACE remains troublingly uncertain, the data are
convincing for bleeding. Regarding MACE, the eff-
ects of “more” remain enigmatic. When it comes
to bleeding events, however, “more” appears to be
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629signiﬁcantly worse. In this study, use of warfarin for
patients with AF was not associated with bleeding
risk, suggesting an opportunity to improve selection
of patients for oral anticoagulation in the setting of
PCI and AF.
If more isn’t better, perhaps less might be? The
most insight into the “more” versus “less” question
is the WOEST (What Is the Optimal Antiplatelet and
Anticoagulant Therapy in Patients With Oral Anti-
coagulation and Coronary Stenting) trial, which
evaluated triple therapy compared with clopidogrel
and warfarin alone in post-PCI patients and found
increases in both MACE and bleeding in the triple
therapy arm (9). Although WOEST was the lone trial
that demonstrated a better strategy with both efﬁ-
cacy and safety endpoints favoring warfarin and
clopidogrel dual therapy over triple therapy, it did
have limitations. WOEST was a small study of
573 patients, of whom only one-quarter received
PCI for acute coronary syndrome, raising questions
of generalizability. Thus, despite being the only
randomized trial to date to explore the role of
triple therapy, WOEST’s treatment strategy received
only a IIb recommendation in the American Heart
Association/American College of Cardiology/Heart
Rhythm Society 2014 guidelines for the manage-
ment of AF (10). Clearly “less” is appealing, but
further study is needed to declare a deﬁnite
frontrunner.
Despite this gap in evidence, more recent in-
vestigations have focused not on further deﬁning the
relative safety and efﬁcacy of DAPT and triple therapy
but rather on redeﬁning the agents in triple therapy.
Rather than comparing “more” versus “less,” inves-
tigation has now centered on “new.” New agents
and new paradigms have been proposed, while there
has yet to be a randomized controlled trial com-
paring conventional DAPT versus triple therapy with
warfarin. Evaluating incorporation of a more potent
antiplatelet agent (i.e., prasugrel) into triple therapy,Sarafoff et al. (11) found increased bleeding events
with prasugrel compared with clopidogrel but no
signiﬁcant difference in ischemic endpoints. Other
trials are underway to evaluate the role of novel
oral anticoagulants, including the REDUAL-PCI trial
investigating the effects of dabigatran as the anti-
coagulant in triple therapy and PIONEER AF-PCI trial
investigating rivaroxaban (12,13). Although these an-
alyses will provide key insights into the potential of
newer agents, their designs compare novel oral anti-
coagulants in combination with either clopidogrel
alone or DAPT versus triple therapy using warfarin, a
P2Y12 inhibitor, and aspirin and not the dual therapy
of WOEST. At best, these trials will offer further evi-
dence to support the use of dual therapy without
aspirin but with no knowledge of their efﬁcacy or
safety compared with clopidogrel and warfarin. At
worst, they may have negative results and continue
the uncertainty surrounding the optimal treatment
strategy for patients with indications for OAC and
DAPT.
Thus, the clinical dilemma remains: what do we
do with patients who have concurrent indications
for OAC and DAPT? The preponderance of evidence
runs contrary to the current practice of using
warfarin with a P2Y12 inhibitor and aspirin. With
mostly observational data and a single, small ran-
domized trial, the data may not be perfect, but they
do paint a picture of uncertain beneﬁt for MACE and
convincing harm with bleeding. When it comes to
antithrombotic therapy, “more” does not appear to
be “better.” Can we replace “more” with a better
alternative? Unfortunately, the answer to date is
“not yet.”
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